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ABSTRACT
Background and the purpose of the study: To develop a simple, rapid and accurate HPLC method 
for the measurement of the venlafaxine and its main metabolites, O-desmethylvenlafaxine and 
O,N-didesmethylvenlafaxine  in  pharmacokinetic  studies  and  therapeutic  drug  monitoring.
Method: Chromatographic separation was achieved with a ChromolithTM Performance RP-18e 
100 mm×4.6 mm column equipped with a Fluorescence detectore (λex 200 nm/λem 300 nm) The   
mobile phase of methanol:water (35:65, v/v) adjusted to pH 2.5 by phosphoric acid was passed 
through the column in an isocratic mode at flow rate of 2 ml/min. The sample preparation 
involved a simple, one-step, extraction with ethyl acetate. 
Results: The calibration curves were linear in the concentration range of 1-300 ng/ml for all 
analytes (r2 > 0.998). The lower limit of quantification was 1 ng/ml for all analytes. Within and 
between day precisions in the measurement of quality control (QC) of samples were in the range 
of 1.8-14.1% for all analytes. 
Conclusion: The developed procedure was used to assess the pharmacokinetics of venlafaxine 
and its main metabolites following oral administration of 75 mg venlafaxine to a healthy 
subject.
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INTRODUCTION
Venlafaxine  (VEN)  (1-[2-(dimethylamino)-1-(4-
methoxy-phenyl) ethyl] cyclohexanol hydrochloride) 
is  a  novel  antidepressant,  which  enhances 
noradrenergic  and  serotonergic  neurotransmission 
through  inhibition  of  noradrenaline  and  serotonin 
reuptake. It also to a lesser extent inhibits, dopamine 
reuptake.  VEN  shows  no  MAO  (Monoamine 
oxidase)  inhibitory  activity  and  has  no  affinity 
for  histamine,  α2  or  β-adrenergic  and  muscarinic 
receptors (1). On the basis of clinical trials, this drug 
appears to lack many side effects associated with 
tricyclic antidepressants.
In  humans,  VEN  is  absorbed  almost  completely 
(92%)  after  oral  intake  and  undergoes  extensive 
metabolism in the liver (Figure 1). About 1% of VEN 
is desmethylated to N-desmethylvenlafaxine (NDV); 
16%  becomes  O,  N-didesmethylvenlafaxine  (DDV) 
and  56%  is  metabolized  to  O-desmethylvenlafaxine 
(ODV)  (2).  Among  all  these  metabolites,  ODV  is 
pharmacologically active with higher concentrations 
and longer half-life than the parent compound (4-9 hrs 
versus  11–13  hrs)  and  significantly  contributes  to  the 
therapeutic effects of VEN. Therapeutic plasma levels of 
VEN usually range from 30 to 200 ng/ml, while the 
corresponding levels of ODV are in the range of 50–
500 ng/ml (3).
Several  methods  can  be  found  in  the  literature  for 
monitoring  the  plasma  levels  of  VEN  and  ODV 
in  biological  samples  (4-11).  The  reported  high 
performance liquid chromatography (HPLC) methods 
have used mass spectrometric (4-6), fluorimetric (7-9), 
and UV detection techniques (10-11). Electrospray mass 
spectrometry has high sensitivity but is expensive and 
not commonly available in most analytical laboratories 
(4-6). Besides, the reported limit of quantification for 
VEN (5,6) is almost the same as fluorimetric (9) or 
higher than coulometric reported methods (12). 
Other published methods are based on the preliminary 
extraction of analytes from the samples using solid 
phase (5, 9, 13) or organic solvents (7,8,10,11). However, 
large (1 ml) sample volume (10-11), high chromatographic 
temperature  (60°C)  (8),  relatively  high  limit  of 
quantification  (values  in  the  range  of  5–50  ng/ml) 
(8-12) and/or long analysis time (≥10 min) (7-12) 
are of those disadvantages.
To  our  knowledge,  there  is  only  one  validated 
HPLC-MS  report  for  simultaneous  determination 
97water (25:75, v/v) for further improvement in peak 
resolution.
Apparatus and chromatographic condition
Low-pressure HPLC pump (K-1001) was connected 
to  a  fluorescence  detector  [excitation  wavelength 
(λex)  200  nm/emission  wavelength  (λem)  300  nm] 
and  an  online  degasser,  all  from  Knauer  (Berlin, 
Germany). A Reodyne model 7725i injector with a 
100 μl loop was used. The data was acquired and 
processed by means of ChromGate chromatography 
software (Knauer, Germany).
Chromatographic  separation  was  achieved  by  a 
ChromolithTM Performance RP-18e 100 mm×4.6 mm 
column (Merck, Darmstadt, Germany) protected by a 
ChromolithTM Guard Cartridge RP-18e 5 mm×4.6 mm 
at room temperature. For the mobile phase, a mixture 
of methanol: water (35:65, v/v) adjusted to pH 2.5 by 
phosphoric acid (final acid concentration about 1.5 mM), 
was delivered in isocratic mode at 2 ml/min flow rate.
Sample preparation
Standard solutions
Stock  solutions  of  the  analytes  (1  mg/ml)  were 
prepared by dissolving suitable amount of each pure 
substance  in  methanol.  Intermediate  pooled  stock 
standard of all compounds in concentrations of 10 
µg/ml were prepared using mobile phase as solvent. 
Standard solutions were prepared freshly every day.
Preparation of calibration standards
From stock solutions of VEN, ODV and DDV (10 
µg/ml)  in  mobile  phase,  standard  solutions  were 
prepared in human drug free plasma obtained from 
healthy volunteers as diluent. The calibration curve 
was performed with standard solutions of the final 
concentration of 1 - 300 ng/ml for VEN, ODV and 
DDV in human plasma respectively.
Extraction procedure
All analytes of interest were extracted from plasma 
by liquid–liquid extraction (LLE). The conditions 
consisted of mixing 200 µl of plasma with 50 µl of 
Internal Standard (IS, 1 µg/ml) and 50 µl of NaOH 
(2N) in a 2 ml Eppendorf polypropylene tube and then 
extracting with 1.2 ml of ethyl acetate. After vertical 
agitation (15 min) and centrifugation (14500×g, 2 
min), the upper organic layer was transferred into a 
conical tube and evaporated under a gentle stream of 
air. The dried extract was re-constituted in 120 µ1of 
the mobile phase and a 100 µl aliquot was injected 
onto the HPLC system.
Application of the method
The  study  protocol  was  approved  by  the  Ethics 
Committee  of  Tehran  University  of  Medical 
Sciences. After obtaining written informed consent, 
to  a  healthy  subject  who  was  fasting  overnight, 
was  administered  a  single  dose  75  mg  of  VEN 
of VEN and its three metabolites (4), and all other 
published methods have only determined VEN and 
ODV as major metabolite. Even though DDV is not 
an active metabolite, it supplies a major metabolite of 
VEN which makes it important for pharmacokinetic 
studies. 
The  objective  of  this  study  was  to  reduce  the 
duration of analysis considerably while maintaining 
the  sensitivity  required  for  the  detection  of  these 
compounds in their therapeutic range by a newly 
developed  monolithic  HPLC  column.  Therefore 
a  simple,  rapid  and  accurate  HPLC  method  was 
developed for the measurement of the VEN, ODV 
and DDV in pharmacokinetic study of VEN as well 
as therapeutic drug monitoring (TDM).
EXPERIMENTAL
Chemicals and reagents
Pure powder of Venlafaxine, O-desmethylvenlafaxine, 
O,N-didesmethylvenlafaxine  (>98%)  were  provided 
by Osvah Pharmaceutical Co. (Tehran, Iran). The 
internal standard of O-desmethyldehydrovenlafaxine 
(Figure 1) was synthesized by the literature method 
(13).  HPLC-grade  methanol  and  analytical  grade 
ethyl  acetate  and  phosphoric  acid  (85%),  were 
supplied  by  Merck  (Darmstadt,  Germany).  Water 
used  in  all  experiments  was  of  Direct-Q®  quality 
(Millipore, France). 
Preparation  of  O-desmethyldehydrovenlafaxine  as 
internal standard
To  a  stirred  solution  of  1-(2-(dimethylamino-1-
(4-methoxyphenyl)ethyl)-cyclohexanol  (venlafaxine 
free  base)  (1387  mg,  5  mmols)  in  CH2Cl2  (30  ml) 
cooled to -10 °C, under N2 was added slowly 10 ml 
(10 mmol) of 1 M solution of BBr3 in CH2Cl2 over a 
period of 5 min. The reaction mixture was warmed to 
0 °C and stirred for 3 hrs. During this period of time a 
gummy precipitate was formed. To the stirred mixture, 
was slowly added 20 ml of 2.5 N sodium hydroxide 
solution, allowed to warm to room temperature and 
stirred for 3 more hrs. The organic solvent was then 
removed by evaporation under reduced pressure. The 
aqueous layer having a pH of 13-14 was extracted with 
ethyl acetate (3×10 ml) and combined EtOAc extracts 
were  dried  over  anhydrous  MgSO4,  filtered  and 
evaporated in vacuum to afford a white solid, which 
was mainly contained O-desmethylvenlafaxine on the 
basis  of  physical  and  spectroscopic  data  consistent 
with literature values (12) and  a minor product. The 
minor  product  which  its  structure  according  to  the 
spectroscopic data was assigned to be the dehydrated 
product  (O-desmethyldehydrovenlafaxine)  separated 
on  silica  gel  (Merck  230-400  mesh)  column  using 
CH2Cl2-CH3OH  (20:1,  v/v)  as  mobile  phase.  The 
purity of the internal standard was studied by the above 
mentioned HPLC method, except for the composition 
of mobile phase, which was changed to methanol: 
A rapid HPLC- fluorescence method for simultaneous determination of venlafaxine   98tablet  (Efexor,  Wyeth-Ayerst,  Canada).  Peripheral 
venous blood samples were taken from the subject 
at predetermined intervals and plasma samples were 
stored at −20 °C until analysis.
RESULTS
Method validation
Selectivity
The  chromatograms  of  analytes  under  study  by 
the present assay method are presented in Figure 2. 
Selectivity  was  indicated  by  the  absence  of  any 
endogenous  interference  at  retention  times  of 
peaks  of  interest  as  evaluated  by  chromatograms 
of  control  human  plasma  (using  more  than  nine 
different blank plasma samples) and plasma spiked 
with compounds. Under the stated conditions, DDV, 
ODV, IS and VEN were eluted at approximately 0.9, 
1.3, 2.2 and 2.7 min respectively with less than 3% 
of RSD for retention times of these analytes (Table 
1). The  system  suitability  factors  were  calculated 
according  to  the  U.S.  pharmacopeia  (14)  and  the 
Analyte Ret. Time(RSD)
(min)
Resolution
(Rs)
Asymmetry
factor (Af)
Plate count
(N)
Capacity 
Factor (K’)
VEN 2.7 (1.2) 1.9 1.1 2916 3.5
ODV 2.2 (2.9 1.6 1.2 1936 2.7
DDV 0.9 (1.5) 1.2 1.2 576 0.5
IS 1.3 (2.6) 3.4 1.2 676 1.2
Table 1. System suitability parameters calculated for DDV, ODV, IS and VEN.
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Figure  1.  Chemical  structure  of  (A)  Ven  lafaxine  and  its  metabolites  and  (B) 
Dehydrodesmethylvenlafaxine as internal standard.
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Figure 2. Chromatograms of (A) blank human plasma, (B) plasma spiked with 125 
ng/ml of VEN, ODV and DDV and (C) plasma of the volunteer 2.5 hrs after single 
oral administration of 75 mg venlafaxine (VEN: 121.3 ng/ml, ODV: 268.7 ng/ml and 
DDV: 47.0 ng/ml). 
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Ardakani et al / DARU 2010 18 (2) 97-102 99results are summarized in table 1. No interference 
was  observed  with  commonly  co-administered 
medication with VEN either because of lack of the 
fluorescence emission or very short/long retention 
time in the developed system.
Linearity
The linearity of the relationship between peak area 
ratios  and  corresponding  concentrations  (which 
were  required  in  this  study)  were  demonstrated 
by  the  correlation  coefficients  obtained  for  the 
regression  lines.  Table  2  presents  the  linearity 
data  from  the  analysis  of  all  analytes.  Each 
concentration level of the curve is based on data of 
three separate runs. The linearity analysis showed 
coefficients of correlation greater than 0.998 for 
all compounds (Table 2).
Accuracy, precision and recovery
Between-  and  within-day  accuracy  and  precisions 
of the method were determined for each compound 
according  to  the  FDA  guidance  for  bioanalytical 
method validation (15). Five replicate spiked samples 
were assayed between- and within-day at four different 
concentrations of each analyte in plasma. Accuracy 
was  calculated  as  deviation  of  the  mean  from  the 
nominal concentration. Precision was expressed as 
the  relative  standard  deviation  of  each  calculated 
concentration. Average recovery of each compound 
was determined by comparing AUC obtained after 
injection  of  the  processed  QC  samples  with  those 
achieved by direct injection of the same amount of 
drug in mobile phase at different concentrations (five 
samples for each concentration level). The results are 
reported in table 3. Accuracy studies of the plasma 
showed acceptable values (92.7-108.1%) for both 
between- and within-day studies (n = 5). The values 
of  within  and  between-day  precision  were  below 
14.1% for all samples. The absolute recoveries of all 
analytes from plasma samples were between 85.0 and 
95.7% as shown in table 3.
Lower Limit of quantification
The  lower  limit  of  quantification  (LLOQ)  was 
defined as the lowest analyte concentration, which can 
be determined with an accuracy and precision <20% 
(15). The calculated LLOQ values were 1 ng/ml with 
RSD and accuracy values between 14.2-16.7% and 
98.7-104.0% for of all analytes respectively.
Stability
Stock solutions of VEN, ODV and DDV in methanol 
were stored at 4ºC for 2 months and all analytes 
appeared to be stable. The samples spiked with the 
analytes  were  stable  after  storage  at  −20ºC  over  3 
months. The stability of wet and dry extracts were 
examined with three replicate spiked quality control 
samples and no significant degradation were observed 
for  IS  and  all  analytes.  No  degradation  in  plasma 
samples  subjected  to  three  cycles  of  freeze–thaw 
was observed. A complete stability study for plasma 
samples has been reported previously (4,16).
Application of the method
The  described  assay  procedure  was  applied 
successfully  to  the  pharmacokinetic  study  of  the 
VEN and its metabolites in one healthy volunteer. 
Plasma concentration-time courses of VEN, ODV, 
and DDV following a single oral dose of VEN are 
shown in figure 3. After 0.5 hrs of administration, 
the  ODV  concentration  in  plasma  considerably 
exceeded  the  plasma  concentration  of  parent 
compound.  However  the  maximum  concentration 
occurred nearly 1 h later in the plasma. In summery, 
the  maximum  plasma  concentrations  were  141.2, 
268.7 and 47.0 ng/ml which were observed nearly 
1.5, 2.5 and 2.5 hrs after administration of VEN, 
ODV and DDV respectively. The elimination half-
lives of VEN, ODV and DDV were calculated about 
5.1, 8.2 and 5.4 hrs respectively. 
DISCUSSION
Long run time in most of HPLC methods may be 
the result of limited flow rate of routine HPLC 
columns  which  might  be  resolved  by  using 
recently  developed  monolithic  HPLC  columns 
such as ChromolithTM. These types of columns have 
a biporous structure which results in higher porosity 
compared  to  usual  columns.  Therefore,  they  could 
be used with high flow rates without significant loss 
Table 2. Linearity data from the analysis of venlafaxine and it`s 
two main metabolites.
Linearity r2
Slope 
(R.S.D)
Intercept 
(R.S.D)
VEN 0.9995 0.0076(2.6) 0.0002(5.6)
ODV 0.9984 0.0041(1.7) 0.0124(6.8)
DDV 0.9986 0.0039(3.1) 0.0095(7.1)
*r2=Coefficient of correlation
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Figure  3. Concentration–time profile of VEN, ODV and DDV 
after administration of 75 mg of single oral dose of venlafaxine 
to one volunteer.
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pressure. Consequently these types of columns achieve 
faster  separation  than  those  of  conventional  HPLC 
columns  and  shorter  runs  will  usually  cause  better 
sensitivities.
The  described  method  has  been  established  as  a 
rapid analytical tool in pharmacokinetic, therapeutic 
drug  monitoring  (TDM)  or  toxicological  studies 
requiring  short  retention  time,  high  precision, 
sensitivity  and  small  volumes  of  plasma  for 
analysis. This method also provided simultaneous 
determination of VEN and its two main metabolites. 
Although no clinical importance has been described 
for the inactive metabolites, measurement of these 
types of analytes in human plasma may be helpful 
in  better  understanding  of  the  metabolism  of  the 
parent compounds. Besides, DDV has very similar 
structure and hence lipophilicity to ODV and reaches 
to a considerable fraction of the active metabolite 
(~30%). Therefore, any interference between ODV 
and  DDV  (because  of  almost  similar  structure) 
may cause significant error in measurement of the 
active metabolite (ODV) concentration. As it was 
mentioned in introduction, Liu et al. have reported 
an HPLC-MS method which separates VEN, ODV, 
DDV  as  well  as  NDV  (4).  Since  only  a  minor 
amount of VEN is metabolized to NDV (about 1%), 
in the current investigation this metabolite was not 
detected and analyzed in human plasma. 
Although not resolving DDV, Vu et al. have reported 
an HPLC method with a tedious and time consuming 
extraction  procedure  (overnight  freezing  of  the 
samples at -20 °C) reaching a maximum recovery 
of 68% for ODV using hexane/isoamyl alcohol as 
extraction solvent (7). In addition to low recovery for 
ODV (52%), the method published by Waschgler et 
al. suffers from inappropriate sensitivity (around 20   
ng/ml) and high chromatographic temperature (60 
°C) (8). Recently Mandrioli et al. have published 
a sensitive HPLC method using SPE as extraction 
procedure (9), however this method has relatively 
long run time and unable to resolve DDV.
Application  of  the  monolithic  HPLC  column 
(ChromolithTM) allowed us to resolve four analytes 
(including IS) more rapidly with a total run time of 
less than 3.5 min producing very sharp peaks with 
lower limit of quantification (LLOQ) of 1 ng/ml. 
In  this  study  a  specific  internal  standard  was 
synthesized  with  maximum  structural  similarity 
which resulted to a shorter overall chromatographic 
run time. As it is clear from figure 2, the IS is 
eluted between ODV and VEN with a retention 
time of 2.2 min. In this study citalopram which 
has been used as IS in many previously published 
VEN  analytical  methods  was  also  examined. 
Although results show that this compound could 
also be used as IS but the run time might lengthen 
up to 4.5 min. The use of ethyl acetate (safe and 
popular solvent) as extracting solvent also produced 
a complete recovery (almost 90%) for all analytes with 
Table 3. Recovery, between and within-day accuracy and precision of the HPLC method for the determination of venlafaxine and its two 
main metabolites (n=5).
    Within-day     Between-day Recovery Concentration
Accuracy R.S.D Accuracy R.S.D % R.S.D (ng/ml)
102.7 14.1 101.8 7.9 91.2 10.1 2.5
VEN
100.7 10.1 99.4 2.2 94.6 11.9 10
90.1 7.8 92.7 2.8 93.7 7.8 25
96.2 3.7 97.7 1.8 95.7 9.1 50
108.1 11.3 103.0 9.5 85.7 12.5 2.5
ODV
105.4 9.1 107.8 1.8 90.7 12.1 10
106.0 7.6 104.3 5.0 89.4 10.8 25
94.9 10.1 97.9 2.2 91.6 11.1 50
104.6 12.1 100.4 8.7 85.0 13.2 2.5
DDV
106.1 9.5 99.4 7.2 86.4 14.1 10
100.4 10.4 101.1 6.1 88.9 10.9 25
101.1 8.4 98.7 4.8 88.8 13.7 50
Ardakani et al / DARU 2010 18 (2) 97-102 101a very clean and interference free baseline.
In  the  last  few  years,  TDM  has  acquired  more 
importance  in  antidepressant  therapy,  especially 
when  abnormal  metabolism  or  low  compliance  is 
suspected, or in the case of polypharmacy. Therefore, 
a simple analytical procedure based on a rapid one 
step extraction and a total run time of less than 3.5 min 
allows the possibility of determination of at least 50 
samples a day in TDM or in pharmacokinetic studies.
CONCLUSION
A  sensitive,  accurate  and  precise  bioanalytical 
method involving a simple liquid–liquid extraction 
of  samples  was  developed  and  validated  for 
determination of VEN and its principal metabolites. 
This  procedure  may  be  recommended  for 
pharmacokinetic and forensic studies as well as for 
therapeutic drug monitoring. 
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